SCHEMBL22801653

SCHEMBL22801653

Cc1ccc2n[nH]c(-c3cccc(C(N)=O)c3)c2c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 3/20 0.64
PARP1 P09874 1/20 0.49
MAPK1 P28482 1/20 0.48
MAPKAPK2 P49137 1/20 0.48
MAPKAPK3 Q16644 1/20 0.48
MAPK6 Q16659 1/20 0.48
MAPKAPK5 Q8IW41 1/20 0.48
FYN P06241 1/20 0.45
ROCK2 O75116 1/20 0.44
ROCK1 Q13464 1/20 0.44
TTK P33981 2/20 0.43
MAPK8 P45983 1/20 0.43
CSF1R P07333 1/20 0.43
FLT1 P17948 1/20 0.43
FLT3 P36888 1/20 0.43
DHODH Q02127 3/20 0.42
CHEK2 O96017 1/20 0.41
PIM1 P11309 1/20 0.41
CCNC P24863 2/20 0.41
CDK8 P49336 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22801737 0.85 MAP2K4 (0.61) MAP2K4MAPK1MAPKAPK2MAPKAPK3MAPK6
SCHEMBL22819366 0.78 MAP2K4 (1.00) MAP2K4PARP1MAPK1MAPKAPK2MAPKAPK3
SCHEMBL22801575 0.76 MAP2K4 (0.62) MAP2K4MAPK1MAPKAPK2MAPKAPK3MAPK6
SCHEMBL22801639 0.76 MAP2K4 (0.60) MAP2K4MAPK1MAPKAPK2MAPKAPK3MAPK6
SCHEMBL22801867 0.73 MAP2K4 (0.62) MAP2K4PARP1FYNTTKMAPK8
SCHEMBL5605353 0.72 PARP1 (0.78) MAP2K4PARP1CSF1RFLT1FLT3
SCHEMBL22801606 0.72 MAP2K4 (0.56) MAP2K4MAPK1MAPKAPK2MAPKAPK3MAPK6
SCHEMBL1675543 0.72 MAPT (0.66)
SCHEMBL22801594 0.71 MAP2K4 (0.61) MAP2K4FYNROCK1MAPK8CSF1R
SCHEMBL3727219 0.71 DHODH (0.71) MAP2K4PARP1CSF1RFLT1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11370770-B2 3-arylindazoles as selective MEK4 inhibitors NORTHWESTERN UNIVERSITY (US) 2022-06-28 US disclosed
US-20200399241-A1 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS NORTHWESTERN UNIVERSITY (US) 2020-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399241-A1 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS MAP4K3, MAPK4, MAP3K4 MAP2K4 39/4885PARP1 2077/4885MAPK1 32/4885
US-11370770-B2 3-arylindazoles as selective MEK4 inhibitors MAP4K3, MAPK4, MAP3K4 MAP2K4 39/4885PARP1 2077/4885MAPK1 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.